Fixed drug eruption due to foscarnet.
A case of fixed drug eruption (FDE) secondary to foscarnet is reported. This drug has recently become available on a compassionate use basis for treatment of cytomegalovirus (CMV) infection which may cause significant disease in immunosuppressed patients. Foscarnet provides a useful alternative to the only licensed anti-CMV drug currently available, namely ganciclovir (DHPG), as it has a different toxicity profile. In particular, it does not appear to cause bone marrow suppression which is of importance in AIDS patients as many of them are taking concurrent zidovudine.
Connolly
G M
GM
Department of Medicine, Westminster Hospital, London.
Gazzard
B G
BG
Hawkins
D A
DA
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy; D003875:Drug Eruptions / Q000150:complications / Q000209:etiology*; D017245:Foscarnet; D006801:Humans; D008297:Male; D010409:Penile Diseases / Q000139:chemically induced* / Q000150:complications; D010746:Phosphonoacetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000998:Antiviral Agents; D017245:Foscarnet; D010746:Phosphonoacetic Acid